Jasper Therapeutics Inc (JSPR NASDAQ) stock market data APIs
$2.3239
0.13(5.6%)
as of September 17, 2025
Try our APIs with
free plan!
Jasper Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
Prev. Close
2.3239
Open
2.4538
High
2.4668
Low
2.2989
52 wk Range
2.265-26.05
Market Cap
39 496 K
Shares Outstanding
16 253 K
EPS
-1.74
Beta
2.781
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Jasper Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Jasper Therapeutics Inc data using free add-ons & libraries
Get Jasper Therapeutics Inc Fundamental Data
Jasper Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -92 729 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -1.9
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Jasper Therapeutics Inc News
New
Jasper Therapeutics to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antib...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). Such inv...
Jasper Therapeutics’ SWOT analysis: briquilimab’s promise amid setbacks
Jasper Therapeutics, Inc. (NASDAQ:JSPR), a biopharmaceutical company focused on developing treatments for hematologic cancers and related diseases, has been navigating a complex landscape of clinical ...
Jasper Reports Wider Loss in Fiscal Q2
Key Points Jasper Therapeutics (NASDAQ:JSPR) reported a GAAP loss per share of $1.74 for Q2 2025. Research and development expenses (GAAP) nearly doubled to $21.2 million in Q2 2025 from $11.3 millio...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
